AstraZeneca Pharma India gets permission from DCGI for Olaparib Film-Coated tablets

AstraZeneca Pharma India Limited has received Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Olaparib Film-Coated tablets 100 mg and 150 mg - additional indication.

Through this approval, Olaparib Film-Coated tablets 100 mg and 150 mg is additionally indicated as a monotherapy for the adjuvant treatment of adult patients with BRCA-mutated HER2- negative high risk early breast cancer who have previously been treated with neoadjuvant or adjuvant chemotherapy.

The receipt of this permission paves way for the launch of Olaparib Film-Coated Tablets 100 mg and 150 mg (Lynparza®) in India for the specified additional indication, subject to the receipt of related statutory approvals and licenses.

Shares of AstraZeneca Pharma India Limited was last trading in BSE at Rs. 3051.10 as compared to the previous close of Rs. 3066.90. The total number of shares traded during the day was 804 in over 193 trades.

The stock hit an intraday high of Rs. 3090.25 and intraday low of 3012.10. The net turnover during the day was Rs. 2447402.00.

Source : Equity Bulls

Keywords

AstraZenecaPharmaIndia INE203A01020 DCGI Olaparib FilmCoatedTablets